{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:15:12Z","timestamp":1783606512653,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmthera.2026.109058","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T22:05:12Z","timestamp":1780869912000},"page":"109058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of Omega-3 fatty acids, fibrates and PCSK9 inhibitors on atherosclerotic plaque burden, composition and stability: Insights from imaging"],"prefix":"10.1016","volume":"285","author":[{"given":"Sherif","family":"Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharmthera.2026.109058_bb0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006981","article-title":"Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: A randomized clinical trial","volume":"6","author":"Alfaddagh","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109058_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/ehjcvp\/pvw034","article-title":"Plaque imaging to refine indications for emerging lipid-lowering drugs","volume":"3","author":"Alkhalil","year":"2017","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2026.109058_bb0015","article-title":"Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by IB-IVUS: A randomized controlled trial","volume":"132","author":"Ando","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109058_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109058_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1204071","article-title":"Quantitative imaging biomarkers of coronary plaque morphology: Insights from EVAPORATE","volume":"10","author":"Buckler","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"40","key":"10.1016\/j.pharmthera.2026.109058_bb0030","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: Final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109058_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100318","article-title":"Cardiac CT angiography in current practice: An American Society for Preventive Cardiology clinical practice statement","volume":"9","author":"Budoff","year":"2022","journal-title":"American Journal of Preventive Cardiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109058_bb0040","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: Interim results of the EVAPORATE trial at 9 months","volume":"117","author":"Budoff","year":"2021","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109058_bb0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2006.02.036","article-title":"Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI","volume":"190","author":"Corti","year":"2007","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109058_bb0050","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109058_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf211","article-title":"Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: A HUYGENS secondary analysis","author":"Di Giovanni","year":"2025","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109058_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100366","article-title":"Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging","volume":"11","author":"Di Giovanni","year":"2022","journal-title":"American Journal of Preventive Cardiology"},{"issue":"9005","key":"10.1016\/j.pharmthera.2026.109058_bb0065","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients","volume":"347","author":"Ericsson","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109058_bb0070","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol","volume":"96","author":"Frick","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2026.109058_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119145","article-title":"Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from the HUYGENS trial","volume":"403","author":"Fujino","year":"2025","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109058_bb0080","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109058_bb0085","first-page":"589","article-title":"Effects of evolocumab on coronary plaque composition and microcalcification activity by coronary PET and CT angiography","volume":"18","author":"Han","year":"2025","journal-title":"JACC: Cardiovascular Imaging"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109058_bb0090","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: A randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"issue":"9500","key":"10.1016\/j.pharmthera.2026.109058_bb0095","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109058_bb0100","article-title":"Effect of pemafibrate on coronary atherosclerosis in a porcine model","volume":"15","author":"Konishi","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109058_bb0105","doi-asserted-by":"crossref","first-page":"e1099","DOI":"10.4244\/EIJ-D-18-01073","article-title":"Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: The LINK-IT trial","volume":"15","author":"Kuroda","year":"2019","journal-title":"EuroIntervention"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109058_bb0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvz329","article-title":"Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography","volume":"116","author":"Lakshmanan","year":"2020","journal-title":"Cardiovascular Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109058_bb0115","first-page":"1475","article-title":"Effects of statins on coronary atherosclerotic plaques: The PARADIGM study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2026.109058_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2021.05.008","article-title":"Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study","volume":"327","author":"Lepor","year":"2021","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109058_bb0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nature Reviews Disease Primers"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109058_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2009.02.068","article-title":"Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome","volume":"54","author":"Motoyama","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2026.109058_bb0135","first-page":"1052","article-title":"Clinical effects of EPA\/DHA on atherosclerotic plaques by MDCT imaging modality","volume":"37","author":"Nagahara","year":"2016","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109058_bb0140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5551\/jat.64063","article-title":"Effect of EPA\/DHA on coronary high-intensity plaques: The AQUAMARINE EPA\/DHA randomized study","volume":"31","author":"Nakao","year":"2024","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109058_bb0145","first-page":"1308","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC: Cardiovascular Imaging"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109058_bb0150","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events: The STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109058_bb0155","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109058_bb0160","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109058_bb0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109058_bb0170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1253\/circj.CJ-15-0813","article-title":"Effects of eicosapentaenoic acid added to pitavastatin on coronary plaque components assessed by integrated backscatter intravascular ultrasound","volume":"80","author":"Niki","year":"2016","journal-title":"Circulation Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109058_bb0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio","year":"2014","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109058_bb0180","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: The ARCHITECT study","volume":"147","author":"P\u00e9rez de Isla","year":"2023","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109058_bb0185","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of statins on serial coronary calcification during atheroma progression and regression","volume":"65","author":"Puri","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109058_bb0190","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/ehjci\/jead063","article-title":"Benefit of icosapent ethyl on coronary physiology assessed by CT angiography fractional flow reserve: EVAPORATE-FFRCT","volume":"24","author":"Rabbat","year":"2023","journal-title":"European Heart Journal Cardiovascular Imaging"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109058_bb0195","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109058_bb0200","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamacardio.2021.3055","article-title":"Association of statin treatment with progression of coronary atherosclerotic plaque composition","volume":"6","author":"van Rosendael","year":"2021","journal-title":"JAMA Cardiology"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109058_bb0205","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109058_bb0210","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109058_bb0215","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109058_bb0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2018.01.062","article-title":"Eicosapentaenoic acid inhibits oxidation of high-density lipoprotein particles in a manner distinct from docosahexaenoic acid","volume":"496","author":"Sherratt","year":"2018","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109058_bb0225","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109058_bb0230","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jacc.2011.09.079","article-title":"Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies","volume":"59","author":"Tearney","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2026.109058_bb0235","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jacl.2025.04.154","article-title":"Effects of PCSK9 inhibitors on morphology of coronary atheroma in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Thakurathi","year":"2025","journal-title":"Journal of Clinical Lipidology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109058_bb0240","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.ATV.20.5.1262","article-title":"Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions","volume":"20","author":"Virmani","year":"2000","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109058_bb0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"Journal of Cardiology"},{"issue":"9567","key":"10.1016\/j.pharmthera.2026.109058_bb0250","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomized open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109058_bb0255","first-page":"977","article-title":"MR imaging of carotid plaque composition during lipid-lowering therapy: A prospective assessment of effect and time course","volume":"4","author":"Zhao","year":"2011","journal-title":"JACC: Cardiovascular Imaging"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:24:28Z","timestamp":1783603468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S0163725826000859"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109058","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Omega-3 fatty acids, fibrates and PCSK9 inhibitors on atherosclerotic plaque burden, composition and stability: Insights from imaging","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109058"}}